Ken Fisher's position in Viridian Therapeutics is currently worth $6.62 Million. That's 0.00% of their equity portfolio (450th largest holding). The investor's estimated purchase price is $9.69 Million, resulting in a loss of 32%.
Avg closing price
Price range
Increased shares by 4.7% (+23.1 Thousand shares)
Q4 2024
Avg closing price
$21.68
Price range
$17.85
-
$25.71
Increased shares by 25.1% (+99.4 Thousand shares)
Q3 2024
Avg closing price
$15.69
Price range
$12.16
-
$23.33
Increased shares by 1.6% (+6.41 Thousand shares)
Q2 2024